Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib DDI Study with CYP and Transporter Probe Cocktail
NCT03561298Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), chronic lymphocytic leukemia (CLL) and 2 more, sponsored by BeiGene. Primary endpoint: Pharmacokinetic parameters of probe drugs. Started Jun 2018; status: completed.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)marginal zone lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03561298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561298.